Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Astex Therapeutics Limited

Simon Teanby Hodgson

Gordon Saxty

Panayiotis Alexandrou Procopiou

Xiao Qing Lewell

Paul Martin Gore

Duncan B Judd

Suzanne Elaine Keeling

David Matthew Wilson

Joelle Le

Lee Andrew Harrison

Colin David Eldred

Hannah Joy Edwards

Thomas Daniel Heightman

Rodolfo Cadilla

Graeme Michael Robertson

Stephen Swanson

Caroline Mary Cook

Yannick Maurice Lacroix

Rachael Anne Ancliff

David Michael Evans

Rebecca Louise Davie

Nigel James Parr

Timothy John Ritchie

Stephen Andrew Thomson

Matthew John Lindon

Ashley Paul Hancock

Deborah Needham

Sadie Vile

Ian Edward David Smith

Heather Hobbs

Michael David Woodrow

Leanda Jane Kindon

Andrew John Walker

Mark Wilkinson

Maria Victoria Vinader Brugarolas

Martin Alistair Hayes

Rachael Ann Ancliff

Pauayiotis Alexandron Procopiou

Christie Schulte

Gail Mills

Andrew Richard Novak

Iain Miller

Paul N Mortenson

Joseph Wendell Wilson

Dave Norman Deaton

Andrew L Larkin

Duncan Bruce Judd

Michael John Stocks

Lee T Schaller

Daniel J Price

Indazole compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing such compounds and their use in therapy.

Compounds

Pyrazole derivatives used as CCR4 receptor antagonists

The present invention relates to a compound of formula (I), or a salt thereof wherein the naphthalene ring is substituted in the 2, 3, 4, 5, 6, 7 or 8 position by R, and Rrepresents &#x2014;CHCHCOOH or &#x2014;CH&#x2550;C(CH)COOH, and to processes for their preparation, to compositions containing them and to their use in the treatment of various inflammatory and/or allergic diseases, such as diseases such as allergic rhinitis.

3-(4-{ [4-(4-{ [3-(3, 3-dimethyl-1-piperidinyl) propyl] oxy} phenyl)-1-piperidinyl] carbonyl}-1-naphthalenyl) propanoic or propenoic acid as H1 and H3 receptor antagonists for the treatment of inflammatory and/or allergic disorders

The present invention relates to a compound which is N-(4-{4-[(6-butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide and salts thereof, processes for its preparation, to compositions containing it and to its use in the treatment of various diseases, such as allergic rhinitis.

Morpholinyl-urea derivatives for use in the treatment of inflammatory diseases

The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.

Substituted piperazines,(1,4) diazepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine H1 and/or H3 antagonists or histamine H3 reverse antagonists

There are provided according to the invention, novel compounds of formula (I) wherein R, R, R, R, R, X, a, b and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

Morpholin-acetamide derivatives for the treatment of inflammatory diseases

There are provided according to the invention, novel compounds of formula (I) wherein R, R, R, R, R, R, X, a, b and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

Compounds useful in the treatment of inflammatory diseases

The present invention relates to novel morpholin-acetamide compounds of formula (I) useful for the treatment of inflammatory diseases. Compounds of formula (I)wherein R, R, R, R, R, X, a, b and Z are as defined in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

Growing community of inventors

Stevenage, United Kingdom

Simon Teanby Hodgson